Form 4: Dentsply Sirona Director Jonathan Mazelsky Reports Changes in Beneficial Ownership

Sentiment:

SEC Form 4 Filing


Jonathan Mazelsky, a director at Dentsply Sirona, reported changes in beneficial ownership due to the acquisition of restricted stock units and phantom stock through dividend accruals.

Summary

  • On January 10, 2025, Jonathan Mazelsky, a director of Dentsply Sirona Inc. [XRAY], reported changes in his beneficial ownership of the company's stock.
  • Mazelsky acquired 115.474 shares of common stock through dividends on restricted stock units (RSUs).
  • He also acquired 38.5332 shares of phantom stock as a result of accrued dividends.
  • Following these transactions, Mazelsky directly owns 13,784.726 shares of Dentsply Sirona common stock and 5,835.5999 shares of phantom stock.
  • The RSUs convert to common stock on a 1:1 basis and vest simultaneously with the dividends.
  • The phantom stock is the economic equivalent of common stock and is payable upon termination of service as a director.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing changes in beneficial ownership. It doesn't convey any particularly positive or negative sentiment about the company's performance or prospects.

Positives

  • The acquisition of additional shares through dividends indicates continued investment in the company by the director.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is common in the dental and healthcare industry. It doesn't necessarily indicate a significant shift in the company's prospects but provides transparency to investors.

Comparison to Industry Standards

  • Form 4 filings are standard practice for publicly traded companies like Dentsply Sirona, ensuring compliance with SEC regulations.
  • Similar filings are made by insiders at comparable companies such as Align Technology (ALGN) and Straumann (STMN), reflecting their holdings and transactions in company stock.
  • The reported transactions are typical for directors receiving stock-based compensation and dividend accruals, aligning with industry norms for executive remuneration.

Stakeholder Impact

  • The filing provides transparency to shareholders regarding the holdings and transactions of a company director.

Key Dates

DateDescription
01/10/2025Date of the reported transactions (acquisition of common stock and phantom stock).
01/14/2025Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.